Vaccibody to present at Jefferies Virtual Healthcare Conference (November 17-19, 2020)

Oslo, Norway, November 12, 2020 – Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, announced today that its CEO, Michael Engsig, and President and CSO, Agnete Fredriksen, Ph.D., will give a presentation of Vaccibody at the Jefferies 2020 Virtual London Healthcare Conference at 12.10 pm CET / 06.10 am EDT on November 19, 2020.

A webcast, which will include a Q&A session, of the event and the presentation material will be available on Vaccibody's website at https://www.vaccibody.com/financial-reports-and-presentations/.

About Vaccibody

Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The Company is using the Vaccibody technology to generate best-in-class therapeutics against cancers and infectious diseases with a high unmet medical need.

Vaccibody is developing cutting-edge DNA vaccines for clinical use, based on a deep understanding of immunological principles. The Company's vaccines specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen-specific immune responses and elicit efficacious clinical responses. By intelligent design, Vaccibody's vaccines can be tailored to induce the desired immune response profile correlating with protection for each specific disease with any given antigen. Vaccibody's clinical products are using an inflammatory chemokine, CCL3, to attract and deliver antigens to APC which has proven to generate unique dominating CD8+ T cell responses with an interesting link to clinical responses in patients with pre-cancerous cervical lesions and solid tumors. The Vaccibody vaccine platform has the potential to address many disease areas with a high unmet medical need.

Vaccibody's development program (VB10.16) is a therapeutic DNA vaccine against HPV16 induced pre-malignancies and malignancies. The first-in-human trial (Phase I/IIa), evaluating the safety and immunogenicity of VB10.16 as monotherapy in women with high grade cervical intraepithelial neoplasia (HSIL; CIN 2/3), has been finalized and published positive 12 months data. The Company is currently running a Phase II trial with VB10.16 in combination with atezolizumab in up to 50 patients with advanced or recurrent cervical cancer. The commercial potential of VB10.16 for the treatment of additional HPV positive cancer indications is being explored. Vaccibody's individualized neoantigen cancer vaccine, VB10.NEO, is currently in

Phase I/IIa and is exclusively outlicensed to Genentech. The Phase I/IIa neoantigen clinical trial is being conducted for patients with locally advanced or metastatic melanoma, non-small cell lung carcinoma, clear renal cell carcinoma as well as urothelial cancer or squamous cell carcinoma of the head and neck. VB10.NEO has demonstrated the ability to induce strong tumor specific immune responses which leads to clinical responses in several patients with locally advanced or metastatic disease. Interim results from Phase I/IIa clinical trial suggests a clear link between selection of high quality neoepitopes, generation of strong neoepitope-specific CD8+ T cell responses and clinical responses. Vaccibody is planning to conduct a Phase 1b trial with VB10.NEO in Europe and U.S. Genentech will be responsible for the development and commercialization of VB10.NEO thereafter.

In 2020, a strategic focus on development of vaccines against infectious diseases to complement the cancer vaccines was announced. Preclinical data generated to date support that the APC-targeted Vaccibody approach generates rapid, strong, broad and long-lasting immunity which opens a potential for efficacy at low and few doses combined with advantageous manufacturing and stability of the product. A comprehensive infectious disease strategy will be presented by end of 2020.

In addition to the license agreement with Genentech, Vaccibody has collaborations with Roche and Nektar Therapeutics and will pursue further collaborations and strategic partnerships to maximize the value of the Company's technology platform.

Vaccibody's shares are traded on Merkur Market, a trading platform operated and wholly owned by Oslo Børs ASA, the Oslo Stock Exchange. The ticker code is VACC-ME.

Further information about Vaccibody may be found at http://www.vaccibody.com

Contact for Vaccibody:

CEO Michael Engsig
Vaccibody AS
Cell: +45 6173 1509
mengsig@vaccibody.com

Vaccibody AS
Oslo Research Park
Gaustadalléen 21
0349 Oslo, Norway

Forward-looking Statements for Vaccibody

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.